A Study of Tocilizumab (RoActemra/Actemra) in Patients With Ankylosing Spondylitis Who Have Had an Inadequate Response to Previous Tumor Necrosis Factor (TNF) Antagonist Therapy

NCT01209689 · clinicaltrials.gov ↗
PHASE3
Phase
TERMINATED
Status
113
Enrollment
INDUSTRY
Sponsor class

Stopped Clinical development program terminated due to failure to achieve efficacy

Conditions

Interventions

Sponsor

Hoffmann-La Roche